Details of the Drug Combination

General Information of Drug Combination (ID: DC67WKW)

• Drug Combination Name: GDC-0084 + Exherin
• Indication: Ewing sarcoma; Status: Investigative [1]
• Component Drugs:
  GDC-0084 (DMA9SEY): N.A.
  Exherin (DMC1I56): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: TC-71
  Zero Interaction Potency (ZIP) Score: 2.647
  Bliss Independence Score: 1.808
  Loewe Additivity Score: 0.107
  LHighest Single Agent (HSA) Score: 3.014

Molecular Interaction Atlas of This Drug Combination

Indication(s) of GDC-0084

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 2	[2]

GDC-0084 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[4]

Indication(s) of Exherin

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Exherin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Neural cadherin (CDH2)	TT1WS0T	CADH2_HUMAN	Binder	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00264433) A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent. U.S. National Institutes of Health.
• [4] Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.
• [5] Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.